19,527 Shares in Abbott Laboratories $ABT Acquired by Directional Asset Management

Key Points

• Directional Asset Management bought a new stake of 19,527 shares in Abbott worth about $2.45 million, representing 2.1% of its portfolio and the firm's 11th largest holding; institutional investors own roughly 75.18% of ABT.
• Abbott beat Q1 estimates with EPS of $1.15 (vs. $1.14) and revenue of $11.16B (vs. $10.99B) and set FY2026 guidance of $5.38–$5.58 EPS and Q2 guidance of $1.25–$1.31, in line with analysts' ~5.49 EPS forecast.
• Multiple brokers have trimmed price targets (e.g., Goldman to $121, Benchmark to $120, Piper to $115), creating negative sentiment despite a consensus "Moderate Buy" target of $119.43; shares trade near the low $90s and the company recently declared a $0.63 quarterly dividend (≈2.7% yield).

Directional Asset Management bought a new stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 19,527 shares of the healthcare product maker's stock, valued at approximately $2,446,000. Abbott Laboratories comprises 2.1% of Directional Asset Management's investment portfolio, making the stock its 11th largest position.

Several other hedge funds have also recently added to or reduced their stakes in ABT. Harbor Capital Advisors Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at $27,000. Cloud Capital Management LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter worth $29,000. Guerra Advisors Inc acquired a new stake in shares of Abbott Laboratories during the third quarter worth $31,000. Bridge Generations Wealth Management LLC acquired a new stake in shares of Abbott Laboratories during the third quarter worth $33,000. Finally, Copia Wealth Management purchased a new stake in shares of Abbott Laboratories during the third quarter valued at $38,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Large-market tailwind: a new IoT medical‑devices market report forecasts strong secular growth for connected and remote-monitoring devices through 2036, supporting Abbott’s device franchises (long-term demand upside). IoT Medical Devices Market Research and Global Forecast Report 2026-2036
• Positive Sentiment: “Most oversold” commentary: coverage noting Abbott as one of the most oversold healthcare names may prompt value-oriented buying and short-covering, supporting near-term rebounds. Abbott is the most oversold healthcare stock as Q1 earnings roll on
• Neutral Sentiment: Elevated investor attention: Zacks and Yahoo note heavy search/interest in ABT, which can increase volatility and trading volume but doesn’t directly change fundamentals. Investors Heavily Search Abbott Laboratories (ABT)
• Neutral Sentiment: Competitive/industry note: unrelated coverage of Intuitive Surgical’s platform refresh highlights competitive dynamics in surgical robotics/devices — worth watching for competitive impact but not an immediate Abbott-specific catalyst. How ISRG Just Secured The U.S. Market
• Negative Sentiment: UBS trims price target to $135 — a reduction in analyst optimism that can cap upside and weigh on investor sentiment despite the company’s solid Q1. UBS Group Cuts Abbott Laboratories NYSE: ABT Price Target to $135.00
• Negative Sentiment: Argus issues a pessimistic forecast for ABT — adds to negative analyst noise and could pressure the stock if other firms follow suit. Argus Issues Pessimistic Forecast for Abbott Laboratories NYSE: ABT Stock Price
• Negative Sentiment: Daiwa downgrades ABT to neutral and sets a $92 target — implies limited near-term upside and may influence short‑term seller behavior. Finviz (Daiwa downgrade note)
• Negative Sentiment: Barclays lowers expectations for ABT — another bearish signal from the sell side that contributes to downward pressure on sentiment and potential re-rating risk. Barclays Has Lowered Expectations for Abbott Laboratories NYSE: ABT Stock Price

Insider Activity at Abbott Laboratories

In related news, EVP Elizabeth C. Cushman sold 263 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $30,397.54. Following the completion of the sale, the executive vice president owned 38,573 shares of the company's stock, valued at approximately $4,458,267.34. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. This trade represents a 0.60% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ABT. The Goldman Sachs Group dropped their price target on Abbott Laboratories from $140.00 to $121.00 and set a "buy" rating on the stock in a research note on Wednesday, April 8th. Benchmark decreased their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating for the company in a report on Friday, April 17th. Piper Sandler dropped their target price on shares of Abbott Laboratories from $135.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, April 17th. Raymond James Financial reduced their price target on shares of Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating for the company in a research report on Friday, April 17th. Finally, Freedom Capital raised shares of Abbott Laboratories from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 29th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $119.43.

Abbott Laboratories Trading Up 0.8%

Shares of NYSE ABT opened at $92.45 on Friday. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a one year low of $90.72 and a one year high of $139.06. The business has a 50-day moving average price of $106.39 and a two-hundred day moving average price of $117.64. The firm has a market capitalization of $161.02 billion, a PE ratio of 25.90, a PEG ratio of 1.53 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The firm's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts predict that Abbott Laboratories will post 5.49 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. Abbott Laboratories's dividend payout ratio is presently 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.